The page cannot be displayed because you are using Internet Explorer version 8 or lower.

Please consider upgrading your browser here

Vi bruger cookies på denne hjemmeside. Ved at bruge hjemmesiden accepterer du vores brug af cookies. Accepter

 
 
 
 

September 8, 2016 - Copenhagen Bioscience Lecture

The Copenhagen Bioscience Lectures are a series of open lectures for all researchers and other interested in and around the Copenhagen area. The lecture on 8 September 2016 will give you an insight in personalised healthcare collaborations from a proteomics lab view. Alain van Gool from Radboud UMC will share his experience.

 

September 8, 2016 - Copenhagen Bioscience Lecture. Theme: personalised healthcare collaborations.

CONCEPT

The Copenhagen Bioscience Lectures are a series of open lectures for all researchers and other interested in and around the Copenhagen area. Every 4 weeks, on a Thursday evening, you are invited to lectures on themes with a general interest for the Novo Nordisk Foundation Research Centers and bioscience researchers in general. Often there will be a cross-disciplinary focus. The lecture on 8 September 2016 will give you an insight in personalised healthcare collaborations from the proteomics centre at Radboud UMC.

PROGRAMME

15:45 Welcome and registration (coffee/tea, fruit, water available)

16:00 Lecture by Alain van Gool, Professor of Personalised healthcare collaborations, Radboud UMC, TNO

          "Translating molecular biomarkers to novel diagnostics and impact in personalized health(care)"

17:00 Lecture by Kim Holmstrøm, R&D Manager at Bioneer A/S, co-founder and chairman of The
Danish Biomarker Network

          "Meeting the requirements for precision medicine: Technological advancements in the
           detection of molecular biomarkers in tissues and cells – the in situ approach"

17:30  Networking with a drink and a bite

18:30 Thank you for a splendid end of day!

 

REGISTRATION

Registration is completely free of charge, but mandatory.

 

ABSTRACT

Exponential developments in diagnostic technologies and of high precision medicines that interfere with selected disease mechanisms have enabled personalized medicine: the right drug to the right patient at the right dose at the right time. We are, however, rediscovering that human physiology is a highly complex system and targeted drugs may not be sufficient to properly restore system disturbances, necessitating the need for system medicine. Personalized health(care) is a umbrella ambition that covers a wide variety of disciplines, whose collaboration is imperative to bring optimal benefit to people including patients. Within this ambition, it is key to translate interdisciplinary molecular research to knowledge and understanding and to actionable decisions for people to maintain and/or improve their health.

Biomarkers have been key tools to drive and enable personalized healthcare. Exponential developments in mass spectrometry, next gen sequencing and imaging have provided highly increased level of insight in human disease and strongly increased the number of candidate biomarkers. However, the disbalance between the enormous volume of biomarker discovery and the still limited diagnostic applications is growing, causing a biomarker innovation gap that is widening every day. Awareness and community building is the most promising path forward and several ongoing initiatives will be presented including those driven by local, national and European technology infrastructures.

 

BIOS

Alain van Gool is professor Personalized Healthcare at the Radboudumc and applied biomarker scientist at TNO, with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. 

His professional background since 1991 is a mix of academia, pharmaceutical industry, applied research institutes, university medical centers. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. While working in Europe, USA and Asia, he and his teams contributed to over 200 projects in various phases of biomarker R&D. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development, and applications in translational scientific research.

Alain is a strong believer of open innovation networks and in his roles he has been collaborating with pharmaceutical, biotechnological, nutriceutical and diagnostic industries, SMEs, biobanks, clinicians, technology providers and information specialists to translate basic research to applied science through public-private partnerships. With that background, he is currently also coordinating the Radboudumc Technology Centers, is Scientific lead Technologies of DTL (the Dutch Techcenter for Life Sciences) and is leading the Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine), thus contributing to the organisation and coordination of local, national and European technology infrastructures.

Complementing his daily work, he enjoys contributing to several scientific advisory boards of start-up enterpreneurs, multinational companies, diagnostic organisations and conference organisers, and is part of several editorial boards of scientific journals.

 

Kim Holmstrøm holds a position as R&D Manager at Bioneer A/S, and he is the co-founder and chairman of The Danish Biomarker Network. He obtained his MSc in chemical engineering in 1989 from the Technical University of Denmark, where he also in 1998 got his PhD degree in Molecular Biology. The last 10 years he has been working with developing technologies for biomarker characterization with emphasis on in situ detection of RNAs (both nc/mRNA) and proteins to improve especially cancer diagnostic methods and to reveal molecular mechanisms. The concept of personalized medicine and the wish to improve diagnostic methods have been the driving forces in his work.

 

FAQs

I would like to know about upcoming Novo Nordisk Foundation Lectures - where can I find information?

You are very welcome to join the 'Novo Nordisk Foundation Research Centers' Linkedin group. There you will find information about upcoming lectures, and much more. Also, you may want to sign up for the weekly announcement with events and deadlines, sent out by the group manager. 

 

What are my transport/parking options getting to the event?

Car: There is a public and paying parking lot at Blågårds Plads, and a few parking spots along the road on Nørre Allé and Blegdamsvej.

Train / Bus:  Closest train station is Nørreport. Take a bus from there. Bus 5A, 3A, and 350S for bus stops: Sankt Hans Torv and Ravnsborggade. Bus 150S, 42, 6A, 184 and 185 for bus stop Rigshospitalet Syd (Fredensgade).

 

Where can I contact the organizer with any questions?

Contact Sophie Labrosse at sfeb@novo.dk

 

How do I cancel my participation?

Please help us respecting our speakers, as well keeping track of the numbers and optimize lecture and catering to the audience by cancelling as soon as you know that you exceptionally will not be able to make it. You can either cancel through Eventbrite or send an email to Sophie Labrosse (sfeb@novo.dk).

 

Can I update my registration information?

Yes, just log in to Eventbrite. Please use this option also in the unlikely event that you need to cancel your registration.

 

Do I have to bring my printed ticket to the event?

No, you do not have to bring your ticket, but registration is mandatory for participation.